lundi 26 juin 2017

Onco Actu du 26 juin 2017

3.3 Prévention - Vaccins

European Court OKs Vaccine Lawsuits Lacking Proof [The Scientist]

4.7 Dép., diag. & prono. - Col de l'utérus

HPV testing leads to earlier detection and treatment of cervical pre-cancer [Queen Mary University of London]

5. Traitements

Existing drugs could benefit patients with bone cancer, genetic study suggests [Sanger Institute]

5.10 Traitements - Essais

NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) [Novartis]

5.12 Immunothérapies

Tumour characteristics could predict immunotherapy success in lung cancer [Cancer Research UK]

5.12.5 Immunothérapies - Pharma

Behind big pharma's race to develop the next wave of cancer therapy [The Telegraph]

5.3 Traitements - FDA, EMA, NICE...

Decision on EMA Relocation Set for November, Council Agrees on Bidding Procedure [RAPS]

5.3.4 Traitements - AMM (FDA, EMA)

Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer [Bayer]

AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma [Aveo]

Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor [Novartis]

5.9.3 EHA

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting [Takeda]

Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial [BMS]

Positive Phase 1b Data for NewLink Genetics' IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, Spain [NewLink Genetics]

Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma [Roche]

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers [Roche]

6.10.1 Politiques (USA)

ASH President Expresses Disappointment with Senate Health Care Bill [ASH]

6.6 Publications

PubPeer Launches Updated Site [The Scientist]

6.7.3 DMP

Electronic health records in Sweden—how can we go from transparency to collaboration? [BMJ Blogs]